CL2013000735A1 - Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico. - Google Patents

Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.

Info

Publication number: CL2013000735A1
Authority: CL; Chile
Prior art keywords: rosacea; imidazol; psoriasis; diseases; skin
Prior art date: 2010-09-16

Application number

CL2013000735A

Other languages

English (en)

Inventor

Mohammed I Dibas

Daniel W Gil

Ken Chow

Liming Wang

Michael E Garst

John E Donello

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-16

Filing date

2013-03-18

Publication date

2013-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000735(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-18 Application filed by Allergan Inc filed Critical Allergan Inc

2013-11-29 Publication of CL2013000735A1 publication Critical patent/CL2013000735A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL2013000735A 2010-09-16 2013-03-18 Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico. CL2013000735A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38337010P	2010-09-16	2010-09-16

Publications (1)

Publication Number	Publication Date
CL2013000735A1 true CL2013000735A1 (es)	2013-11-29

Family

ID=44675870

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
CL2013000734A CL2013000734A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
CL2013000736A CL2013000736A1 (es)	2010-09-16	2013-03-18	Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.
CL2013000735A CL2013000735A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2013000733A CL2013000733A1 (es)	2010-09-16	2013-03-18	Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CL2013000734A CL2013000734A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
CL2013000736A CL2013000736A1 (es)	2010-09-16	2013-03-18	Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CL2013000733A CL2013000733A1 (es)	2010-09-16	2013-03-18	Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.

Country Status (29)

Country	Link
US (9)	US8653123B2 (es)
EP (13)	EP3698789A1 (es)
JP (4)	JP2013541527A (es)
KR (7)	KR101840500B1 (es)
CN (5)	CN105412092B (es)
AR (4)	AR083017A1 (es)
AU (4)	AU2011301901B2 (es)
BR (4)	BR112013006362A2 (es)
CA (8)	CA3077732A1 (es)
CL (4)	CL2013000734A1 (es)
CY (3)	CY1121024T1 (es)
DK (9)	DK3078376T3 (es)
ES (10)	ES2788051T3 (es)
HK (5)	HK1185541A1 (es)
HU (5)	HUE049573T2 (es)
IL (4)	IL225278A (es)
MX (4)	MX2013003008A (es)
MY (4)	MY191369A (es)
NZ (1)	NZ608751A (es)
PL (7)	PL3053576T3 (es)
PT (7)	PT3053576T (es)
RU (4)	RU2013116763A (es)
SG (4)	SG188570A1 (es)
SI (5)	SI3050563T1 (es)
TR (1)	TR201909249T4 (es)
TW (4)	TW201240661A (es)
UA (1)	UA112973C2 (es)
WO (4)	WO2012037453A1 (es)
ZA (4)	ZA201302194B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2880578T3 (es)	2009-02-13	2021-11-24	Allergan Inc	Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
AU2011203867B2 (en)	2010-01-11	2015-12-03	Nalpropion Pharmaceuticals Llc	Methods of providing weight loss therapy in patients with major depression
US8653123B2 (en) *	2010-09-16	2014-02-18	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
EP2734200A1 (en) *	2011-07-22	2014-05-28	Allergan, Inc.	Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
AU2012340806B2 (en)	2011-11-21	2017-10-19	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en)	2014-11-28	2017-08-15	Samsung Electronics Co., Ltd.	Display screen or portion thereof with a graphical user interface
CN108310442B (zh) *	2017-01-17	2021-08-27	台北科技大学	眼科用组合物
KR102050506B1 (ko)	2017-06-20	2019-11-29	한국식품연구원	망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) *	2018-07-09	2021-03-23	成都倍特药业股份有限公司	一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN112552314B (zh) *	2018-08-24	2022-03-04	杭州阿诺生物医药科技有限公司	Sting激动剂小分子抗肿瘤化合物及其应用
BR112023021140A2 (pt) *	2021-04-16	2023-12-12	Ads Therapeutics Llc	Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE147619T1 (de)	1992-05-13	1997-02-15	Sandoz Ag	Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5459133A (en) *	1992-06-05	1995-10-17	Telor Ophthalmic Pharmaceuticals, Inc.	Methods and products for treating presbyopia
EP0729459B1 (en)	1993-11-15	2003-03-12	Schering Corporation	Phenyl-alkyl imidazoles as h3-receptor antagonists
US5474979A (en)	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) *	1998-05-12	1999-11-17	Schwarz Pharma Ag	Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) *	2000-07-14	2004-10-28	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en)	2001-05-03	2002-12-26	Allergan Sales Inc.	Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) *	2003-05-27	2004-12-09	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
JP2007528020A (ja) *	2003-07-14	2007-10-04	コーニンクレッカフィリップスエレクトロニクスエヌヴィ	投影装置
BRPI0414277A (pt) *	2003-09-12	2006-11-07	Allergan Inc	métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular vasculopathies
MXPA06013649A (es)	2004-05-25	2007-07-09	Sansrosa Pharmaceutical Dev In	Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US20050277584A1 (en)	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
AU2005290075A1 (en) *	2004-09-24	2006-04-06	Allergan, Inc.	4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en)	2005-05-10	2011-04-26	Allergan, Inc.	Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en)	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7297679B2 (en)	2005-07-13	2007-11-20	Allergan, Inc.	Cyclosporin compositions
US20070082070A1 (en) *	2005-10-11	2007-04-12	Stookey Evangeline L	Treating skin disorders
US7902247B2 (en)	2008-01-09	2011-03-08	Allergan, Inc.	Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2010091209A1 (en)	2009-02-06	2010-08-12	Allergan, Inc.	Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
ES2880578T3 (es)	2009-02-13	2021-11-24	Allergan Inc	Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US8653123B2 (en) *	2010-09-16	2014-02-18	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

2011
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en active Application Filing
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active IP Right Grant
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Application Filing
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Application Discontinuation
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active IP Right Grant
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active IP Right Grant
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active IP Right Grant
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en active Application Filing
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en active Application Filing
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko not_active Application Discontinuation
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en active Application Filing
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
2013
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
- 2013-11-19 HK HK13112925.0A patent/HK1185541A1/zh unknown
- 2013-11-19 HK HK13112920.5A patent/HK1185540A1/zh unknown
- 2013-11-19 HK HK13112917.0A patent/HK1185538A1/zh unknown
- 2013-11-19 HK HK13112919.8A patent/HK1185539A1/zh unknown
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
- 2018-12-27 HK HK18116626.8A patent/HK1257416A1/zh unknown
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown

Also Published As

Publication number	Publication date
DK2616068T3 (en)	2016-08-29
US20120136036A1 (en)	2012-05-31
HUE038698T2 (hu)	2018-11-28
CA2812197A1 (en)	2012-03-22
EP3050563B1 (en)	2018-05-09
EP2616068B1 (en)	2016-07-13
HK1185540A1 (zh)	2014-02-21
EP3078376B1 (en)	2019-03-27
WO2012037453A1 (en)	2012-03-22
BR112013006352A2 (pt)	2016-06-28
DK2616069T3 (en)	2016-12-19
PL3050564T3 (pl)	2020-06-01
HK1185541A1 (zh)	2014-02-21
CY1122958T1 (el)	2021-10-29
PT3338777T (pt)	2020-05-06
KR20200091507A (ko)	2020-07-30
US8492422B2 (en)	2013-07-23
NZ608751A (en)	2015-04-24
TWI591058B (zh)	2017-07-11
JP2013537236A (ja)	2013-09-30
AU2011301856C1 (en)	2016-09-08
US8501796B2 (en)	2013-08-06
AU2011301847B2 (en)	2016-02-11
KR20140003407A (ko)	2014-01-09
MY173846A (en)	2020-02-24
PL3348264T3 (pl)	2020-08-24
HK1185538A1 (zh)	2014-02-21
SI3050564T1 (sl)	2020-02-28
MX2013003009A (es)	2013-06-28
EP2616069B1 (en)	2016-11-16
AR083019A1 (es)	2013-01-23
SG188573A1 (en)	2013-04-30
US20160354346A1 (en)	2016-12-08
CN105412092A (zh)	2016-03-23
PL3338777T3 (pl)	2020-07-13
AR083017A1 (es)	2013-01-23
BR112013006362A2 (pt)	2016-06-28
EP3053576A1 (en)	2016-08-10
KR101840500B1 (ko)	2018-03-20
EP3050564A1 (en)	2016-08-03
EP3348264B1 (en)	2020-01-01
CN105412092B (zh)	2020-11-17
KR102354097B1 (ko)	2022-01-20
MX2013003008A (es)	2013-06-28
SI3338777T1 (sl)	2020-08-31
AU2011301847A1 (en)	2013-05-02
KR20130114140A (ko)	2013-10-16
ES2904479T3 (es)	2022-04-05
PL2616069T3 (pl)	2017-04-28
CN103221045A (zh)	2013-07-24
AU2011301932C1 (en)	2016-09-01
RU2612351C2 (ru)	2017-03-07
RU2013116403A (ru)	2014-10-27
CA2811559A1 (en)	2012-03-22
AR083020A1 (es)	2013-01-23
DK3053576T3 (en)	2018-08-20
TW201305116A (zh)	2013-02-01
CL2013000736A1 (es)	2013-07-12
TW201240662A (en)	2012-10-16
TR201909249T4 (tr)	2019-07-22
EP2616069A1 (en)	2013-07-24
SI3050563T1 (sl)	2018-10-30
ES2788051T3 (es)	2020-10-20
JP6045495B2 (ja)	2016-12-14
US20140057958A1 (en)	2014-02-27
RU2013116541A (ru)	2014-10-27
SG188572A1 (en)	2013-04-30
KR20130105658A (ko)	2013-09-25
RU2013116763A (ru)	2014-10-27
UA112973C2 (uk)	2016-11-25
JP6073229B2 (ja)	2017-02-01
CA3122745A1 (en)	2012-03-22
CY1122809T1 (el)	2021-05-05
PT2616068T (pt)	2016-09-13
PL2616068T3 (pl)	2016-11-30
TW201305117A (zh)	2013-02-01
ES2607084T3 (es)	2017-03-29
ES2760920T3 (es)	2020-05-18
SG188570A1 (en)	2013-04-30
KR101840501B1 (ko)	2018-05-04
WO2012037484A1 (en)	2012-03-22
DK3050563T3 (en)	2018-08-13
AU2011301901A1 (en)	2013-05-02
CN103200941A (zh)	2013-07-10
CL2013000734A1 (es)	2013-11-08
AU2011301932B2 (en)	2016-02-25
WO2012037499A1 (en)	2012-03-22
EP3338777A1 (en)	2018-06-27
EP3078376A1 (en)	2016-10-12
JP2013541527A (ja)	2013-11-14
CL2013000733A1 (es)	2013-08-23
CA3116249A1 (en)	2012-03-22
JP2013540749A (ja)	2013-11-07
MY191369A (en)	2022-06-20
EP2616068A1 (en)	2013-07-24
BR112013006320B1 (pt)	2022-08-30
US20150148394A1 (en)	2015-05-28
EP3050563A1 (en)	2016-08-03
AR083018A1 (es)	2013-01-23
PL3053576T3 (pl)	2018-11-30
ES2684055T3 (es)	2018-10-01
CN103200942A (zh)	2013-07-10
WO2012037490A1 (en)	2012-03-22
US20120142746A1 (en)	2012-06-07
IL225278A0 (en)	2013-06-27
MY168763A (en)	2018-12-04
AU2011301932A1 (en)	2013-05-02
EP3338777B1 (en)	2020-02-05
KR102104760B1 (ko)	2020-04-27
ES2613509T3 (es)	2017-05-24
IL225278A (en)	2015-11-30
HUE039090T2 (hu)	2018-12-28
HUE048725T2 (hu)	2020-09-28
CA2812197C (en)	2024-01-02
ES2781681T3 (es)	2020-09-04
IL225282A0 (en)	2013-06-27
KR20140005154A (ko)	2014-01-14
ZA201302291B (en)	2013-11-27
EP3053576B1 (en)	2018-05-16
DK3050564T3 (da)	2019-11-25
ES2737230T3 (es)	2020-01-10
KR20200044147A (ko)	2020-04-28
CN103200941B (zh)	2015-12-16
CY1121024T1 (el)	2019-12-11
BR112013006320A2 (pt)	2016-06-21
HUE049573T2 (hu)	2020-10-28
US20130289088A1 (en)	2013-10-31
AU2011301901B2 (en)	2016-02-11
CA2812195A1 (en)	2012-03-22
DK3078376T3 (da)	2019-06-24
EP2616066B1 (en)	2016-07-13
CA3079450A1 (en)	2012-03-22
EP3636263B1 (en)	2021-11-03
EP3659600A1 (en)	2020-06-03
PT3348264T (pt)	2020-04-02
PL3050563T3 (pl)	2018-12-31
TW201240661A (en)	2012-10-16
ZA201302193B (en)	2013-11-27
CA3077732A1 (en)	2012-03-22
ES2687420T3 (es)	2018-10-25
RU2013116405A (ru)	2014-10-27
SG188571A1 (en)	2013-04-30
HK1185539A1 (zh)	2014-02-21
US8492557B2 (en)	2013-07-23
MY161607A (en)	2017-04-28
PT3050564T (pt)	2019-12-11
EP3348264A1 (en)	2018-07-18
DK3348264T3 (da)	2020-03-23
EP2616067B1 (en)	2016-05-18
DK3636263T3 (da)	2022-01-10
KR101952457B1 (ko)	2019-02-26
CA2812191C (en)	2021-04-13
IL225281A0 (en)	2013-06-27
JP2013537237A (ja)	2013-09-30
US20120122945A1 (en)	2012-05-17
EP2616067A1 (en)	2013-07-24
BR112013006355A2 (pt)	2016-06-28
EP3636263A1 (en)	2020-04-15
US20120149746A1 (en)	2012-06-14
PT3050563T (pt)	2018-10-01
ZA201302194B (en)	2013-11-27
HK1257416A1 (zh)	2019-10-18
PT2616069T (pt)	2016-12-06
MX2013003004A (es)	2013-06-28
DK3338777T3 (da)	2020-04-20
US8653123B2 (en)	2014-02-18
US8853251B2 (en)	2014-10-07
CA2812191A1 (en)	2012-03-22
EP3050564B1 (en)	2019-09-04
EP3698789A1 (en)	2020-08-26
IL225280A0 (en)	2013-06-27
KR20190022895A (ko)	2019-03-06
MX2013003002A (es)	2013-06-28
ZA201302288B (en)	2013-11-27
PT3053576T (pt)	2018-10-08
AU2011301856A1 (en)	2013-05-02
CN103209694A (zh)	2013-07-17
KR102139905B1 (ko)	2020-07-31
HUE047476T2 (hu)	2020-04-28
SI3053576T1 (sl)	2018-11-30
ES2593612T3 (es)	2016-12-12
EP2616066A1 (en)	2013-07-24
SI3348264T1 (sl)	2020-07-31
US20130296394A1 (en)	2013-11-07

Publication	Publication Date	Title
CL2013000735A1 (es)	2013-11-29	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
ECSP12012310A (es)	2012-12-28	5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CL2015001731A1 (es)	2015-08-28	Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
GT200900230A (es)	2011-11-29	4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2014001158A1 (es)	2014-09-12	Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
CO6440531A2 (es)	2012-05-15	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2014001752A1 (es)	2014-10-10	Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
UY33776A (es)	2012-06-29	Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UY35115A (es)	2014-05-30	Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
UY31228A1 (es)	2009-03-02	Ariloxazoles sustituidos y su uso
CL2013000018A1 (es)	2013-05-10	Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
BR112012029746A2 (pt)	2016-08-09	composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
CO6811867A2 (es)	2013-12-16	Cannabinoides para uso en el tratamiento del dolor neuropático
CL2014001861A1 (es)	2014-11-07	Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
UY33372A (es)	2011-12-30	?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2013002129A1 (es)	2013-12-20	Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
CL2013003700A1 (es)	2014-07-18	Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
CL2014002845A1 (es)	2015-01-30	Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CL2013000502A1 (es)	2014-01-03	Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
BR112014031706A8 (pt)	2021-10-19	Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
CL2015001881A1 (es)	2015-11-06	Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2013001445A1 (es)	2014-03-28	Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
DOP2010000400A (es)	2011-01-31	7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos